Phase 2 Study of Daraxonrasib in Recurrent KRAS-Mutant Biliary Tract Cancer

Authors
Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2026
The purpose of this study is to evaluate the anti-tumor efficacy of daraxonrasib monotherapy in patients with unresectable or advanced/metastatic, KRAS-mutant BTC who have progressed on or are intolerant of 1st line systemic therapy.
Epistemonikos ID: e600072b36d08831265f3e6262095193cb2f8d08
First added on: Aug 29, 2026